cd38 inhibitor and 5-amino-1mq synergy nad+ CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents Inhibition of CD38 and supplementation
Inhibition of CD38 and supplementation of nicotinamide riboside ameliorate lipopolysaccharide induced microglial and astrocytic neuroinflammation by increasing NAD+ PMC Small Molecule CD38 Inhibitors: Synthesis of 8 Amino N1 inosine 5 monophosphate, Analogues and Early Structure Activity Relationship The Pharmacology of CD38 NADase: An emerging target for cancer and aging diseases PMC Targeting NAD+ Synthesis to Potentiate CD38 Based Immunotherapy of Multiple Myeloma ScienceDirect Frontiers Nicotinamide N methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome CD38 expressing macrophages drive age related NAD+ decline Nature Metabolism
Pay in 4 interest-free payments of $6.51 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9





